To verify the improvements of L.p R3 to efficacy of ICI in anti-tumor treatment, MC38 colon cancer mouse model was established to assess the effects of oral administration of L.p R3 and combinatorial treatment of L.p R3 with PD-1. This evidence concerns the gene PDCD1 and colonic neoplasm.